Last 48 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.73 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 24.08 | 59.01 | 73.72 | 25.24 | 10.58 | 34.52 | 17.08 | 11.06 | 23.06 | 56.95 | 77.99 | 22.70 | — | 58.43 | 66.14 | 64.88 | 52.20 | 80.20 | 69.93 | 120.69 | 171.16 |
| — | +70.9% | +331.7% | +128.1% | -54.1% | -39.4% | -78.1% | -51.3% | — | -2.5% | +17.9% | -65.0% | — | -27.1% | -5.4% | -46.2% | -69.5% | -76.6% | -83.4% | -42.3% | +35.4% | |
| P/B Ratio | 1.83 | 2.76 | 3.10 | 2.45 | 1.45 | 2.54 | 1.36 | 0.94 | 1.36 | 2.16 | 2.23 | 2.54 | 2.63 | 2.70 | 3.25 | 2.75 | 2.29 | 5.16 | 4.46 | 5.70 | 8.46 |
| — | +8.5% | +128.1% | +159.3% | +6.5% | +17.9% | -39.1% | -62.8% | -48.1% | -20.2% | -31.3% | -7.7% | +14.5% | -47.6% | -27.0% | -51.8% | -72.9% | -42.2% | -80.0% | -42.3% | +33.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.5% | 100.0% | 100.0% | 85.4% | 73.9% | -472.8% | -465.3% | 100.0% | -807.9% | -1098.3% | 62.6% | 91.3% | 228.6% | 80.9% | -748.0% | -670.4% | -637.0% | -628.6% | -542.9% | -1082.9% | -453.6% |
| — | +121.1% | +121.5% | -14.6% | +109.1% | +56.9% | -842.9% | +9.5% | -453.3% | -1457.5% | +108.4% | +113.6% | +135.9% | +112.9% | -37.8% | +38.1% | -40.4% | +15.0% | +32.1% | -112.6% | +5.4% | |
| Operating Margin | -651.7% | -1707.7% | -1472.3% | -668.1% | -428.9% | -808.9% | -772.2% | -726.6% | -1059.9% | -1589.0% | -1998.6% | -394.0% | 7297.4% | -1093.3% | -973.5% | -888.1% | -811.1% | -795.5% | -700.6% | -1282.0% | -625.6% |
| — | -111.1% | -90.7% | +8.1% | +59.5% | +49.1% | +61.4% | -84.4% | -114.5% | -45.3% | -105.3% | +55.6% | +999.7% | -37.4% | -38.9% | +30.7% | -29.6% | +20.4% | +33.5% | -78.0% | +2.7% | |
| Net Margin | -609.9% | -1779.8% | -1392.3% | -639.5% | -416.2% | -735.2% | -710.8% | -687.6% | -1001.2% | -1489.5% | -2112.6% | -371.3% | 6894.2% | -1019.2% | -909.8% | -818.1% | -835.5% | -853.5% | -717.6% | -1305.3% | -632.0% |
| — | -142.1% | -95.9% | +7.0% | +58.4% | +50.6% | +66.4% | -85.2% | -114.5% | -46.1% | -132.2% | +54.6% | +925.1% | -19.4% | -26.8% | +37.3% | -32.2% | +14.2% | +31.7% | -82.1% | +1.2% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -53.5% | -19.0% | -15.8% | -14.9% | -13.5% | -13.8% | -13.5% | -13.8% | -14.1% | -14.0% | -14.6% | -10.3% | -12.7% | -11.4% | -10.8% | -8.5% | -11.0% | -13.3% | -11.0% | -14.7% | -7.6% |
| — | -37.4% | -16.8% | -7.6% | +4.0% | +1.4% | +7.5% | -34.4% | -11.0% | -23.0% | -35.9% | -21.2% | -15.0% | +14.1% | +1.8% | +42.3% | -45.5% | -48.4% | +17.0% | -71.0% | +23.2% | |
| ROA | -40.6% | -14.5% | -13.2% | -12.0% | -10.8% | -11.1% | -10.7% | -10.5% | -10.9% | -11.5% | -12.0% | -8.4% | -10.4% | -9.5% | -9.0% | -7.0% | -8.7% | -10.3% | -8.7% | -11.8% | -6.2% |
| — | -30.4% | -22.9% | -14.5% | +0.6% | +3.2% | +10.4% | -25.2% | -5.0% | -20.5% | -32.9% | -19.5% | -19.3% | +7.7% | -3.7% | +40.3% | -40.9% | -44.5% | +12.1% | -77.3% | +16.9% | |
| ROIC | -44.0% | -13.3% | -13.4% | -12.8% | -11.7% | -12.7% | -11.5% | -10.9% | -11.1% | -11.5% | -10.9% | -8.9% | -10.9% | -9.6% | -9.6% | -9.0% | -10.2% | -10.0% | -8.7% | -11.5% | -6.6% |
| — | -4.4% | -16.5% | -17.8% | -5.3% | -10.7% | -6.0% | -21.8% | -2.3% | -19.4% | -13.6% | +0.7% | -7.1% | +3.7% | -9.8% | +21.7% | -55.0% | -18.8% | +23.3% | -45.8% | +40.4% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.14 | 0.38 | 0.10 | 0.13 | 0.14 | 0.13 | 0.14 | 0.15 | 0.24 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.12 | 0.08 | 0.08 | 0.07 |
| — | +186.8% | -29.7% | -15.2% | -42.3% | +24.0% | +31.0% | +42.9% | +119.5% | -7.5% | -1.1% | +1.0% | +3.8% | -3.6% | +40.1% | +40.7% | +48.7% | +72.5% | -44.7% | -43.5% | -4.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.08 | 6.31 | 6.65 | 6.10 | 5.08 | 6.21 | 5.19 | 4.90 | 5.77 | 6.73 | 7.21 | 9.03 | 8.67 | 9.72 | 9.41 | 9.32 | 9.61 | 6.55 | 7.24 | 6.94 | 6.11 |
| — | +1.6% | +28.0% | +24.6% | -12.0% | -7.7% | -27.9% | -45.8% | -33.4% | -30.8% | -23.4% | -3.1% | -9.9% | +48.3% | +30.1% | +34.3% | +57.3% | -21.6% | -2.6% | -29.9% | -36.3% | |
| Quick Ratio | 5.08 | 6.31 | 6.65 | 6.10 | 5.08 | 6.21 | 5.19 | 4.90 | 5.77 | 6.73 | 7.21 | 9.03 | 8.67 | 9.72 | 9.41 | 9.32 | 9.61 | 6.55 | 7.24 | 6.94 | 6.11 |
| — | +1.6% | +28.0% | +24.6% | -12.0% | -7.7% | -27.9% | -45.8% | -33.4% | -30.8% | -23.4% | -3.1% | -9.9% | +48.3% | +30.1% | +34.3% | +57.3% | -21.6% | -2.6% | -29.9% | -36.3% | |
| Interest Coverage | — | -207.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NTLA stock.
Intellia Therapeutics, Inc.'s current P/E is -3.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Intellia Therapeutics, Inc.'s current operating margin is -651.7%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Intellia Therapeutics, Inc.'s business trajectory between earnings reports.